Innospec Inc. (IOSP) Stock Price & How to Invest

Innospec Inc. is an Englewood, Colorado specialty chemicals company that listed in 1998 as Octel Corp and took the Innospec name in 2006. It reports three segments. Fuel Specialties, the profit engine, sells combustion improvers, detergents, cold flow additives and stabilizers to refiners, fuel marketers and the aviation gasoline market, and produced ~$185.7 million of revenue at a ~36.6 percent gross margin in the second quarter of 2026. Performance Chemicals supplies surfactants and formulation ingredients for personal care, home care and industrial customers, contributing ~$190.3 million at a much thinner ~17.3 percent gross margin. Oilfield Services sells production and completion chemicals plus drag reducing agents, which let pipeline operators push more volume through existing lines, and added ~$115.4 million. About ~2,450 employees serve customers across the Americas, EMEA and Asia Pacific.

The second quarter of 2026 was the cleanest print Innospec has delivered in some time. Revenue of ~$491.4 million rose ~12 percent, operating income climbed ~16 percent to ~$39.7 million, and every segment grew. The balance sheet is the standout: no drawn debt, ~$250.2 million of cash, and an undrawn ~$250 million revolving facility running to 2028, which funds a semi-annual dividend of ~92 cents per share, a ~$75 million buyback authorized in May 2026, and bolt-on acquisitions. Set against that is the quality of the growth. Adjusted EBITDA of ~$50.1 million was only marginally ahead of last year, adjusted EPS of ~$1.27 was essentially flat, and a good share of the revenue gain came from price, mix and currency rather than volume. Cash conversion has been poor so far in 2026, with ~$24.8 million of first-half operating cash flow against ~$31.7 million of capital and software spending, largely because receivables built by ~$70.2 million.

Performance Chemicals runs at roughly a ~17 percent gross margin, so modest moves in raw material cost or personal care demand swing a disproportionate amount of operating income, and the North Carolina site has not yet returned to normal production. Fuel Specialties gross margin slipped ~1.5 points year over year on an adverse Americas sales mix, and its AvGas line saw volumes fall ~21 percent, a business tied to leaded aviation gasoline where the long-run regulatory direction points toward unleaded alternatives. Both Fuel Specialties and Oilfield Services recorded adverse movements in doubtful-debt provisions during the quarter, which deserves attention given how concentrated Oilfield Services is in the Americas. Most of the revenue and cost base sits outside the United States, so reported results carry real currency translation noise and the ~2 to ~3 point currency tailwind in the second quarter can reverse. Innospec also continues to disclose a misappropriation of inventory in Brazil first reported in its 2023 annual report, against which it has lodged civil and criminal claims with no offsetting recovery asset recorded and no significant developments since.

3 analysts publish price targets on IOSP, averaging $101.00 against a $93.85 price as of August 2026, or +7.6%. The published targets run from $93.00 to $110.00, a narrow spread, and the ratings split 3 buy, 0 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full IOSP forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Innospec Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Fuel Specialties carries the earnings. Fuel Specialties supplied roughly ~38 percent of second-quarter revenue but close to ~59 percent of pre-corporate segment operating income, at a ~36.6 percent gross margin. The most optimistic published target, $110.00, assumes this works close to its best case.

The case against. Performance Chemicals runs at roughly a ~17 percent gross margin, so modest moves in raw material cost or personal care demand swing a disproportionate amount of operating income, and the North Carolina site has not yet returned to normal production. The most pessimistic target, $93.00, is roughly what IOSP is worth if this bites instead.

Read the full bull and bear case on IOSP, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Innospec Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.84 billion, with Q2 2026 revenue of ~$491.4 million, up ~12% year over year
• Diluted EPS (TTM): ~$4.90, including ~$1.25 GAAP (~$1.27 adjusted) in Q2 2026
• Operating and net margin: ~8.1% operating, ~6.6% net on a trailing basis
• P/E: ~19x trailing, ~16x forward
• EV / EBITDA: ~11x, on an enterprise value of about ~$2.11 billion
• Net cash and dividend: ~$250 million net cash with no drawn debt; ~$1.84 annual dividend, a yield near ~2.0%

At roughly ~$94 a share and a market cap near ~$2.31 billion, Innospec trades at about ~19 times trailing earnings and ~1.25 times sales, with enterprise value pulled down to ~$2.11 billion by the net cash position. Trailing growth rates flatter the picture because the comparison base includes a ~$155.6 million non-cash settlement charge taken in 2024 when the company bought out its UK pension scheme, cutting that year's net income to ~$35.6 million against ~$139.1 million in 2023. Return on equity near ~9 percent and return on invested capital near ~11 percent read as solid rather than exceptional, which is roughly where the multiple sits.

Other names that sit close to IOSP: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get IOSP exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so IOSP sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where IOSP fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

IOSP pairs an unusually clean balance sheet and a high-margin fuel additives franchise with a thin-margin personal care business and lumpy oilfield demand, which is why it trades nearer a diversified industrial multiple than a premium specialty ingredients one.

Whether IOSP is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is IOSP a buy or a sell?, and where the stock could go from here in the IOSP stock forecast.

For income investors, whether IOSP pays a dividend and how the payout looks is covered in does IOSP pay a dividend? And to weigh IOSP against a peer, read the full side-by-side comparisons: IOSP vs NEU and IOSP vs SHEL.